Elizabeth Budde, MD, discusses the phase 3 data behind the mosunetuzumab plus polatuzumab vedotin combination in the SUNMO trial.
Elizabeth Budde, MD
Advertisement
Articles by Elizabeth Budde, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Accepts NDA for AD109 for Treatment of Adults With Obstructive Sleep Apnea
2
Men Face Higher Odds of Later-Stage Diagnosis Across 20 Cancer Types
3
Clinical Forum Events Highlight the Evolving Landscape of Obesity Management
4
Workforce Preparation for Fall Immunization Season Starts Now
5